SEARCH
Admedus Corp.
Minneapolis, MN 55437 USA
Phone
Fax
Research Sector Tissue Impants
Summary Description A new generation of tissue bio-implants that more easily integrate into recipient tissue, show less capacity for rejection and have the potential to replace many of the products that surgeons currently use.
Management Julian Chick, Chief Operating Officer; Stephen Mann, Chief Financial Officer and Company Secretary; Lynne Bradshaw, Director-Marketing; Danny Zanardo, Director-Sales; Helen Wray, VP of Operations Click here for Financial Data
Keywords: Regenerative Tissue, Bio-Implants, Rejection, Surgery, Heart
Updated: Mar. 18, 2016
Description
Admedus Corp. is the American arm of Australian ASX-listed Admedus Ltd a diversified healthcare company focused on developing and commericalizing technologies with global potential. Working with ......view more
Products / Services
CardioCel - A solution for life. CardioCel is currently undergoing regulatory approval in the US but is now available for sale in Europe. CardioCel is a new type of cardiovascular scaffold that......view more
Technology / Differentiation
Our patented ADAPT tissue engineering process has enabled our scientific team to create a biological scaffold that more readily promotes native tissue in-growth. Tissue bio-implants developed usin...view more
Market / Customers
Cardiovascular Surgery......view more